Skip to content

Insmed INSM EV / sales

EV / sales at other companies

Incyte logo
IncyteINCY
2.9×+0.6×
Amgen logo
AmgenAMGN
6.6×+0.1×
ALN
Alnylam PharmaceuticalsALNY
9.9×-4.7×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.4×
Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
28.9×-18.5×

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$20.76B+155%
Enterprise value$20.76B+142%
P/S25.3×+4.0×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp
FCF margin-112.5%-35.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Calculated from Insmed’s reported figures.

Based on the most recent quarter.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's EV / sales?
Insmed (INSM) reported EV / sales of 43× in Q1 2026.
How has Insmed's EV / sales changed year-over-year?
Insmed's EV / sales increased by 12.6% year-over-year, from 38.2× to 43×.
What is the long-term trend for Insmed's EV / sales?
Over 5 years (2020 to 2025), Insmed's EV / sales has grown at a 25.0% compound annual growth rate (CAGR), from 20.1× to 61.3×.
What does EV / sales mean?
What the whole business costs relative to its annual sales.
How do you interpret EV / sales?
A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
How does EV / sales compare across companies?
Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.